Ceramide nanoliposomal - Keystone Nano

Drug Profile

Ceramide nanoliposomal - Keystone Nano

Alternative Names: Ceramide NanoLiposome; CNL; KN 001; KN-001 - Keystone Nano; KN-01; Nanoliposomal ceramide

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Keystone Nano
  • Class Antineoplastics; Ceramides; Neuroprotectants; Sphingolipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Jan 2017 US FDA approves IND application for Ceramide nanoliposome in Cancer
  • 04 Jan 2017 Chemical structure information added
  • 18 Oct 2016 Nanoliposomal ceramide - Keystone Nano receives Orphan Drug status for Liver cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top